Navigation Links
Peripheral Arterial Disease Costlier to Treat Than Heart Trouble
Date:1/23/2008

Prolonged recovery, potential for repeat treatments to blame, study finds

WEDNESDAY, Jan. 23 (HealthDay News) -- It costs about 5 percent more to treat people with peripheral arterial disease (PAD) than those with coronary artery disease (CAD), a U.S. study finds.

Both PAD (blocked abdomen and leg arteries) and CAD (blocked heart arteries) are treated with the same methods, including medication, surgery and endovascular techniques such as balloon angiography and stenting. The type of treatment depends on the location and severity of the disease.

Treatment tends to be more successful in CAD patients, which may explain why PAD costs more to treat, the study authors said.

"Patients with heart disease who get treated with a stent typically are doing just fine when seen six to 12 months later," principal investigator Dr. Michael R. Jaff, director of the Massachusetts General Hospital Vascular Center in Boston, said in a prepared statement. "Patients with PAD have to be seen frequently, and many of the treatments don't last as long, so it costs more to care for these patients."

This is because PAD-related blockages tend to be longer and more spread out, while CAD-related blockages are short and near the origin of the arteries.

In this study, Jaff and colleagues analyzed Medicare costs from 1999 to 2005 and found that, on average, the cost of initial treatment and one year of follow-up for PAD patients was $50,110, compared with $47,515 for CAD patients.

The researchers also noted that PAD is on the rise in the United States. About 8.2 percent of the Medicare patients included in the study had PAD in 1999, compared with about 9.5 percent in 2005. Most of the PAD patients were aged 65 or older.

Among the other findings from the study:

  • PAD patients with diabetes cost more to treat than those without diabetes, likely because those with diabetes have more extensive and severe PAD due to the effects of diabetes. About one-third of people with diabetes who are 50 or older have PAD, according to the American Diabetes Association.
  • Minimally invasive endovascular treatment tended to be more successful than surgery in PAD patients. This may be due to the prolonged recovery time for surgery and the potential for repeated treatments.

"These data suggest that future trials of PAD therapy should take into account the high cost of treating these patients, particularly those with diabetes mellitus," Jaff said. "When therapies work equally well, but there are cost advantages of one over the other, the less expensive therapy should be tried first."

The study was presented Monday at the annual International Symposium on Endovascular Therapy, in Hollywood, Fla.

About 8 million to 12 million Americans have PAD, which increases the risk of other cardiovascular disease, such as heart attack, stroke and aneurysm. PAD symptoms include limb pain, especially when walking, as well as numbness, skin discoloration and open sores that don't heal. However, many people with PAD have no symptoms.

More information

The Society for Vascular Surgery has more about peripheral arterial disease.



-- Robert Preidt



SOURCE: International Symposium on Endovascular Therapy, news release, Jan. 21, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
2. Riverside First to Offer New Treatment for Peripheral Arterial Disease
3. New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
4. Spectranetics Receives Reimbursement Approval in Belgium for Lead Removal and Peripheral Atherectomy Products
5. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
6. American College of Physicians publishes "Peripheral Arterial Disease"
7. Peripheral Artery Disease Up Sharply Among U.S. Women
8. Asymptomatic peripheral artery disease prevalence is rising
9. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
10. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
11. Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Peripheral Arterial Disease Costlier to Treat Than Heart Trouble
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... Ball at The Pierre Hotel in New York, NY, on December 3rd, to ... dignitaries and physicians attended the annual event, which raised over $1 million - ...
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... "I ... said an inventor from Winchester, Va. "I thought that if the nebulizer had a ... treatments rather than fearing them." , He developed the patent-pending NEBY to avoid the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical Institute ... The name change aligns the entire company with its existing Quality Insights ... , “We are very proud of the achievements associated with the West Virginia ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)...   TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...
(Date:12/8/2016)... , Dec. 8, 2016  Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...
Breaking Medicine Technology: